Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.12659/MSM.924700 http://scihub22266oqcxt.onion/10.12659/MSM.924700 32366816!7218962!32366816     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Sci+Monit 2020 ; 26 (ä): e924700 Nephropedia Template TP {{tp|p=32366816|t=2020. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development |pdf=|usr=}}{{32366816}} gab.com Text An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development JO: Med Sci Monit http://www.kidney.de/pget.php?&tw=1&pmid=32366816 #FOAvip The first outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, Hubei Province, China, in late 2019. The subsequent COVID-19 pandemic rapidly affected the health and economy of the world. The global approach to the pandemic was to isolate populations to reduce the spread of this deadly virus while vaccines began to be developed. In March 2020, the first phase I clinical trial of a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine, mRNA-1273, which encodes the spike protein (S protein) of SARS-CoV-2, began in the United States (US). The production of mRNA-based vaccines is a promising recent development in the production of vaccines. However, there remain significant challenges in the development and testing of vaccines as rapidly as possible to control COVID-19, which requires international collaboration. This review aims to describe the background to the rationale for the development of mRNA-based SARS-CoV-2 vaccines and the current status of the mRNA-1273 vaccine. Twit Text FOAVip An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development ????Med Sci Monit http://www.kidney.de/pget.php?&tw=1&pmid=32366816 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32366816 #FOAvip English Wikipedia <ref>{{Cite pmid|32366816}}</ref> An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development #MMPMID32366816 Wang F; Kream RM; Stefano GB Med Sci Monit 2020[May]; 26 (ä): e924700 PMID32366816show ga The first outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, Hubei Province, China, in late 2019. The subsequent COVID-19 pandemic rapidly affected the health and economy of the world. The global approach to the pandemic was to isolate populations to reduce the spread of this deadly virus while vaccines began to be developed. In March 2020, the first phase I clinical trial of a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine, mRNA-1273, which encodes the spike protein (S protein) of SARS-CoV-2, began in the United States (US). The production of mRNA-based vaccines is a promising recent development in the production of vaccines. However, there remain significant challenges in the development and testing of vaccines as rapidly as possible to control COVID-19, which requires international collaboration. This review aims to describe the background to the rationale for the development of mRNA-based SARS-CoV-2 vaccines and the current status of the mRNA-1273 vaccine. |*Betacoronavirus/immunology[MESH] |*Viral Vaccines[MESH] |2019-nCoV Vaccine mRNA-1273[MESH] |COVID-19[MESH] |COVID-19 Vaccines[MESH] |Coronavirus Infections/immunology/*prevention & control[MESH] |Humans[MESH] |Pandemics/*prevention & control[MESH] |Pneumonia, Viral/immunology/*prevention & control[MESH] |RNA, Messenger/immunology[MESH] |RNA, Viral/immunology[MESH] |SARS-CoV-2[MESH] |Spike Glycoprotein, Coronavirus/genetics/immunology[MESH]An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development (epmc).pdf DeepDyve Pubget Overpricing